Genital Herpes Simplex Type 2
Conditions
Keywords
HSV, Herpes, Genital Herpes
Brief summary
This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.
Interventions
BIOLOGICALObservational
Sponsors
Genocea Biosciences, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Completion of Study GEN-003-002 2. Receipt of at least 1 dose of GEN-003 (any dose combination) in Study GEN-003-002. 3. Collection of at least 45 of 56 anogenital swabs during the Month 11 to 12 swab collection period in Study GEN-003-002. 4. Willing and able to provide written informed consent. 5. Willing to perform and comply with all study procedures, including attending clinic visits as scheduled. 6. For each swab collection period, willing to not use HSV-2 antiviral therapy from 14 days before the swab collection period through the end of the period.
Exclusion criteria
1. Any important protocol deviation in Study GEN-003-002. 2. Use of HSV-2 antiviral therapy within 14 days before the beginning of Swab Collection Period 1. 3. Use of topical steroids or antiviral medication in the anogenital region within 14 days before the beginning of Swab Collection Period 1. 4. Use of tenofovir, lysine, or other medication or supplement known or purported to affect HSV outbreak frequency or intensity within 14 days before the beginning of Swab Collection Period 1. 5. Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months before the Visit 1, any dose of corticosteroids within 30 days before Visit 1, or high-dose inhaled corticosteroids \[\>960 µg/day of beclomethasone diproprionate or equivalent\]) or other immunosuppressive agents. 6. Presence or history of autoimmune disease, regardless of current treatment. 7. Receipt of a vaccine containing HSV-2 antigens other than GEN-003. 8. Pregnant women. 9. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study. 10. Onset of an AESI since Month 12 in study GEN-003-002. 11. Other active, uncontrolled comorbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (percent of anogenital swabs positive for HSV-2 DNA by PCR) | Up to 48 months post-dose |
| Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (magnitude of HSV-2 viral shedding by PCR) | Up to 48 months post-dose |
Secondary
| Measure | Time frame |
|---|---|
| Long-term effect of GEN-003 on HSV-lesion rate (percent of days with genital lesions present) during the swab collection periods | Up to 48 months post-dose |
| Long-term immune responses to GEN-003 (Serum IgG levels assessed by ELISA) | Up to 48 months post-dose |
| Long-term immune responses to GEN-003 (Serum HSV-2 neutralizing antibody levels assessed by a colorimetric neutralization assay) | Up to 48 months post-dose |
| Long-term immune responses to GEN-003 (Spot-forming units (SFUs), fold rise, responder rate assessed by GrB ELISPOT) | Up to 48 months post-dose |
Countries
United States
Outcome results
None listed